|
|
|
|
| LEADER |
03414nmm a2200313 u 4500 |
| 001 |
EB000713532 |
| 003 |
EBX01000000000000000566614 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
140122 ||| eng |
| 020 |
|
|
|a 9789400967984
|
| 100 |
1 |
|
|a Reinhoudt, D.N.
|e [editor]
|
| 245 |
0 |
0 |
|a Structure-Activity Relationships of Anti-Tumour Agents
|h Elektronische Ressource
|c edited by D.N. Reinhoudt, T.A. Connors, H.M. Pinedo, K.W. van de Poll
|
| 250 |
|
|
|a 1st ed. 1983
|
| 260 |
|
|
|a Dordrecht
|b Springer Netherlands
|c 1983, 1983
|
| 300 |
|
|
|a VIII, 293 p
|b online resource
|
| 505 |
0 |
|
|a 1. Introduction -- 2. Strategy for the Discovery and Development of Novel Anticancer Agents -- 3. Quantitative Structure-Activity Relationship Studies Around Cytotoxic Drugs -- 4. Alkylating Prodrugs in Cancer Chemotherapy -- 5. Structure-Activity Relationships for Anti-Tumour Platinum Complexes -- 6. Bioreductive Alkylation — Naturally Occurring Quinones as Potential Candidates -- 7. Structure-Activity Relationships in Doxorubicin Related Compounds -- 8. Structure-Activity Relationships Among Antitumour Quinones -- 9. In Vitro Oxidative Activation: A Model for the Cytotoxic Action of 9-Hydroxy Ellipticine Derivatives -- 10. DTIC: A Springboard to New Antitumour Agents -- 11. Nitrosoureas -- 12. Oxazaphosphorine Cytostatics: Structure-Activity Relationships, Selectivity and Metabolism, Regional Detoxification -- 13. Studies on Antitumour Antibiotics, Low Molecular Weight Immuno-Modifiers and Their Analogs and Derivatives
|
| 653 |
|
|
|a Pharmacology
|
| 653 |
|
|
|a Oncology
|
| 700 |
1 |
|
|a Connors, T.A.
|e [editor]
|
| 700 |
1 |
|
|a Pinedo, H.M.
|e [editor]
|
| 700 |
1 |
|
|a van de Poll, K.W.
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b SBA
|a Springer Book Archives -2004
|
| 490 |
0 |
|
|a Developments in Pharmacology
|
| 028 |
5 |
0 |
|a 10.1007/978-94-009-6798-4
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-94-009-6798-4?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 615
|
| 520 |
|
|
|a The Workshop series of the "Koningin Wilhelmina Fonds" is a feature of the interest of this Foundation to promote research and education in the field of cancer, aiming to improve prognosis of the cancer patient. For almost a century, surgery has now been the main treatment modality for the cancer patient. During the past 50 years radiation therapy has developed as a second important modality of treatment. However, neither of the two modalities are able to cure the majority of cancer patients, as the disease is so often metastasized at presentation. Cancer chemotherapy is a modality which does have the potential to cure patients with this advanced stage of disease. In recent years the three modalities have been combined more and more, and here is one of the reasons why the prospectives for the cancer patient have improved so much. In addition, certain types of cancers, such as testicular car cinoma, childhood tumors, choriocarcinoma, non Hodgkin lymphomas and others, can now indeed often be cured by chemotherapy alone, even if the disease is advanced. The combination of drugs and the use of new drugs have greatly contributed to this development. There are two main groups of new drugs: analogs and new structures. A great number of analogs of conventional structures have been developed during the past ten years. A typical example of this group is adriamycin, which is an analog of dau nomycin
|